One of the companies working on a coronavirus vaccine said Wednesday that it’s on track to finish enrollment for a phase three study before October.
Moderna also said it plans to make the vaccine affordable below $40 per dose for most customers.
This as all drug companies are being closely watched to see what they plan to charge for COVID-19 treatments.
In June, Biotech Gilead Sciences revealed that its remdesivir drug would cost more than $500 a vial for people with private health insurance.
Moderna is just one of several U.S. drug companies racing to come up with a successful vaccine. Novavax and Pfizer have also had promising vaccine results so far.
- Campus varsity football team to miss two games, fans remain hopeful for remainder of season
- KBI: Death investigation in Iola surrounding 34-year-old man
- Michael Jordan, Hamlin partner on NASCAR team for Wallace
- KDOL seeing rise in unemployment claim fraud stemming from identity theft
- Sublette school district goes remote after numerous students and employees were quarantined for COVID-19